Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1993]

Acalabrutinib plus venetoclax with or without obinutuzumab versus...

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA

Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )

Primary IVIG supplementation reduces the risk of high-grade infections in...

Dr Heloise Cheruvalath - Medical College of Wisconsin, Milwaukee, USA

Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM ( Dr Heloise Cheruvalath - Medical College of Wisconsin, Milwaukee, USA )

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows...

Dr Paolo Caimi - Cleveland Clinic, Cleveland, USA

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma ( Dr Paolo Caimi - Cleveland Clinic, Cleveland, USA )

Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced...

Dr Peter Abdelmessieh - Fox Chase Cancer Center, Philadelphia, USA

Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM ( Dr Peter Abdelmessieh - Fox Chase Cancer Center, Philadelphia, USA )

Pembrolizumab after chemo demonstrates promising activity in low-risk cHL

Prof Christine Mauz-Koerholz - Justus Liebig University, Giessen, Germany

Pembrolizumab after chemo demonstrates promising activity in low-risk cHL ( Prof Christine Mauz-Koerholz - Justus Liebig University, Giessen, Germany )

Analysis of pre-treatment biomarkers associated with toxicity and durable...

Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA

Analysis of pre-treatment biomarkers associated with toxicity and durable responses in idecabtagene vicleucel therapy for RRMM ( Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA )

Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene...

Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA

Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in RRMM ( Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA )

Bispecific antibody therapy for lymphoma patients failing CAR T-Cell therapy

Dr Matthew Matasar - Rutgers Cancer Institute, New Jersey, USA

Bispecific antibody therapy for lymphoma patients failing CAR T-Cell therapy ( Dr Matthew Matasar - Rutgers Cancer Institute, New Jersey, USA )

Teclistamab-based induction regimens demonstrate manageable safety and efficacy...

Prof Marc Raab - Heidelberg Myeloma Center, Heidelberg, Germany

Teclistamab-based induction regimens demonstrate manageable safety and efficacy in patients with transplant-eligible NDMM ( Prof Marc Raab - Heidelberg Myeloma Center, Heidelberg, Germany )

Addition of tafasitamab to lenalidomide plus rituximab significantly improves...

Dr Christina Poh - Fred Hutchinson Cancer Centre, Seattle, USA

Addition of tafasitamab to lenalidomide plus rituximab significantly improves efficacy in R/R follicular lymphoma ( Dr Christina Poh - Fred Hutchinson Cancer Centre, Seattle, USA )

Blinatumomab added to chemotherapy improves disease-free survival in newly...

Dr Rachel Rau - University of Washington, Seattle, USA

Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL ( Dr Rachel Rau - University of Washington, Seattle, USA )

Outcomes and survival in newly diagnosed, older, AML patients from the Beat AML...

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA

Outcomes and survival in newly diagnosed, older, AML patients from the Beat AML master trial in the venetoclax/azacitidine age ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )

More from ecancer